Research and development

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
수요일, 4월 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

Valbiotis to launch its 100% natural dietary supplement for the management of hypercholesterolemia on the French market in May

Retrieved on: 
수요일, 4월 10, 2024
Cholecalciferol, LDL, CRM, Cholesterol, Cardiovascular disease, Medicine, Digital, Dietary supplement, Business, Risk, Patient, Pharmacy, DSM-IV codes, ERP, Research, Stroke, Pharmacist, Business development, Executive Committee, HEART, Artery, Research and development, Omega-3 fatty acid, Safety, Enterocyte, Lipid metabolism, General practitioner, Marketing, Practitioner, Sleep, Hypercholesterolemia, Pharmaceutical industry

The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."

Key Points: 
  • The natural and innovative characteristics of this product clearly position Valbiotis®PRO Cholestérol as a leader in the lifestyle and dietary management of hypercholesterolemia, a major risk factor for cardiovascular disease."
  • Available behind the counter in pharmacies, the dietary supplement will also be sold without a prescription with a pharmacist’s recommendation.
  • It comprises a new generation of dietary supplements with active ingredients of natural origin, acting on several targets for comprehensive management.
  • A principal mechanism controls intestinal cholesterol absorption, while a complementary mechanism acts on hepatic metabolism for a comprehensive approach to the management of hypercholesterolemia.

Sharon Personal Care to Introduce Innovative New Haircare Technology at in-cosmetics 2024

Retrieved on: 
목요일, 4월 4, 2024
Elasticity, Protein, Research and development, Moringa, Hyaluronic acid

SharoHYAL(R) Moringa is proven to improve hair elasticity, resilience by 6%; moisturization by 45%

Key Points: 
  • Trezzo sull'Adda, Italy--(Newsfile Corp. - April 4, 2024) - Sharon Personal Care, a global supplier of innovative, environmentally friendly ingredient solutions for a broad range of personal care products, will introduce SharoHYAL® Moringa, an innovative hair restoration solution, at in-cosmetics 2024, taking place April 15-20 in Paris.
  • In clinical testing, SharoHYAL Moringa has proven to increase hair moisturization by 45% after only one treatment.
  • Sharon Personal Care will be providing demonstrations of SharoHYAL Moringa throughout in-cosmetics 2024 in their booth, 1K70.
  • Sharon will also host a press conference on Wednesday, April 17 at 9:00 a.m. to introduce a groundbreaking multifunctional preservation system.

Innodata Shareholder Lawsuit Filed By Block & Leviton – Investors Who Have Lost Money Should Contact The Firm

Retrieved on: 
수요일, 4월 10, 2024
Research, Certification, Block & Leviton, Growth, District court, United States district court, Defendant, News, AI, Nature, Silicon, Complaint, Goldengate, Research and development, Wolfpack, Marketing

and is brought on behalf of investors that incurred damages on their purchases in Innodata, Inc. securities between May 9, 2019 and February 14, 2024, inclusive.

Key Points: 
  • and is brought on behalf of investors that incurred damages on their purchases in Innodata, Inc. securities between May 9, 2019 and February 14, 2024, inclusive.
  • A class has not yet been certified, and until certification occurs, you are not represented by an attorney.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.
  • You can learn more about us at our website, www.blockleviton.com , or call (617) 398-5600 or email [email protected] with any questions.

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
화요일, 4월 9, 2024
Major histocompatibility complex, CPI, Cell, Entrepreneurship, Oncology, Immunotherapy, DLL4, Patient, Neoplasm, Data, Tumor microenvironment, VEGF, Checkpoint, Doctor of Philosophy, MD, Natural killer T cell, News, AACR, MHC, Research and development, Therapy, MHC-I, Antibody, Immune system, PD-L1, San Diego Convention Center, NK, PD-1, Vaccine

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.

Key Points: 
  • Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.
  • The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.
  • Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors.
  • A copy of the presentation materials can be accessed on the News & Events section under “ Presentations ” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Innodata Inc. - INOD

Retrieved on: 
월요일, 4월 8, 2024
Research, Prior, Innodata, News, Ext, LLP, AI, Nature, Complaint, Pomerantz, Research and development, Action Replay, Wolfpack, Court

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Innodata Inc. (“Innodata” or the “Company”) (NASDAQ: INOD).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Innodata Inc. (“Innodata” or the “Company”) (NASDAQ: INOD).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether Innodata and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against InMode, Innodata, Fox Factory, and X and Encourages Investors to Contact the Firm

Retrieved on: 
월요일, 4월 8, 2024
Research, Class Action, Growth, Palo Alto Networks, Federation, Defendant, Food and Drug Administration, Dermatology, News, AI, Nature, Silicon, Complaint, P.C, Goldengate, Research and development, Fox Factory, Confidentiality, Injury, Wolfpack, Marketing, Dentist, FDA

InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
  • For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Retrieved on: 
금요일, 4월 5, 2024
CD4, CD8, AMP, Development, Antigen, Immunotherapy, Colorectal cancer, Memory, Patient, Lung, GM-CSF, Biomarker, DNA, Epitope, Cancer, Granzyme B, BRAF, Lymph, IL2, Circulating tumor DNA, Phenotype, Neoplasm, Research and development, Immunization, Therapy, Vaccination, CRC, V600E, Immune system, Melanoma, Granzyme, Phase 1, Amphetamine, Nature Medicine, Annual general meeting, Vaccine

Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.

Key Points: 
  • Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
  • A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
  • The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
  • "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.

Zulu Network Secures $3 Million in Pre-Seed Funding to Revolutionize Bitcoin Layer 2

Retrieved on: 
금요일, 4월 5, 2024
Architecture, Ecosystem, EVM, Entrepreneurship, CGV, Financial services, Research, Community Participation, UTXO, Bitcoin network, Alpha, Research and development, Decentralized finance, BTC, L3, Cryptocurrency

Decentralized Bitcoin Bridge Infrastructure: Zulu Network is building the first decentralized Bitcoin bridges to connect all Bitcoin Layer 2s and the entire crypto ecosystem to the Bitcoin ecosystem.

Key Points: 
  • Decentralized Bitcoin Bridge Infrastructure: Zulu Network is building the first decentralized Bitcoin bridges to connect all Bitcoin Layer 2s and the entire crypto ecosystem to the Bitcoin ecosystem.
  • It is reported that the Alpha version of the Zulu Network Test Network will be launched on April 5th.
  • “This is just the beginning for Zulu Network,” says Eric Lifson, Co-Founder at Zulu Network.
  • “We are very excited about having the opportunity to revolutionize the Bitcoin Network and want to give special thanks to all investors participating in this funding.

Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update

Retrieved on: 
금요일, 4월 5, 2024
TME, Development, FAP, Doctor of Philosophy, Patient, Doxorubicin, Tumor microenvironment, Royal Marsden Hospital, MD, AACR, Research and development, Institute of Cancer Research, Poster, Heterotrimeric G protein, BST, AIM, Fine chemical

Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.

Key Points: 
  • Christina Coughlin, MD, PhD, Head of Research & Development and Simon Bennett, DPhil, Chief Business Officer, will be attending the conference with colleagues.
  • A copy of the abstract will be available on Avacta’s website at: https://avacta.com/about/scientific-resources/ .
  • Christina Coughlin will provide a video presentation overview examining the data presented in the poster.
  • Alastair Smith, Avacta Chief Executive Officer, will also be hosting a webinar on Wednesday, April 10 2024 at 5.30pm BST to discuss the data.